drugset
Drugs / MIP-1095 I-131
last change Nov 2023 re-read 3 minutes ago

MIP-1095 I-131

also known as 131I-MIP-1095 · IODINE I 131 MIP-1095

Other / unclassified

Developed for
castration-resistant prostate carcinoma
Investigated by
Memorial Sloan Kettering Cancer Center · Progenics Pharmaceuticals, Inc.

Trials 1

today NCT03030885 · Ph 1
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03030885 Jan 2017 → Apr 2019 castration-resistant prostate carcinoma Memorial Sloan Kettering Cancer Center Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as MIP-1095 I-131 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297853 ↗
Known as 131I-MIP-1095 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03030885 ↗
Known as IODINE I 131 MIP-1095 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297853 ↗
Modality Other / unclassified “131I-MIP-1095 is a targeted radiotherapeutic” PMID 37812518 ↗ Nov 2023